The addition in 2012 of a daily, oral biomedical option (pre-exposure prophylaxis, or PrEP) to the HIV prevention toolkit represented an important step in the effort to reach the goal of ending HIV/AIDS as a public health threat by 2030. The recent development of highly effective, long-acting PrEP options makes it a pivotal moment for global HIV prevention efforts. Just as the introduction and scale up of antiretroviral therapies in the early 2000s offered an opportunity to dramatically shift the trajectory of HIV, there is optimism that as new long-acting products, including those that have already received regulatory approval and others that may receive approval, become more widely available, it may be possible to significantly limit new HIV infections and fundamentally transform the global HIV response.
Please join the CSIS Bipartisan Alliance for Global Health Security for a conversation regarding the opportunities and challenges to ensuring a comprehensive set of PrEP options are available, affordable, and acceptable to populations most vulnerable to HIV. Katherine E. Bliss, Senior Fellow and Director of Immunizations and Health Systems Resilience, CSIS Global Health Policy Center, will be joined by Jared Baeten, Senior Vice President for Clinical Development at Gilead Sciences, Alex Rinehart, Medicines Development Leader, Prevention, ViiV Healthcare, Ambassador John Nkengasong, U.S. Global AIDS Coordinator and Senior Bureau Official for Global Health Security and Diplomacy, U.S. Department of State, and Ntombizonke Tembe, DREAMS Ambassador, Eswatini.
This event is made possible through the generous support of the Bill & Melinda Gates Foundation.
